Authors
John T Walkup, Michael J Labellarte, Mark A Riddle, Daniel S Pine, Laurence Greenhill, Rachel Klein, Mark Davies, Michael Sweeney, Howard Abikoff, Sabine Hack, Brian Klee, James McCracken, Lindsey Bergman, John Piacentini, John March, Scott Compton, James Robinson, Thomas O'Hara, Sherryl Baker, Benedetto Vitiello, Louise Ritz, Margaret Roper
Publication date
2001/4/26
Journal
New England Journal of Medicine
Volume
344
Issue
17
Pages
1279-1285
Publisher
Massachusetts Medical Society
Description
Background
Drugs that selectively inhibit serotonin reuptake are effective treatments for adults with mood and anxiety disorders, but limited data are available on the safety and efficacy of serotonin-reuptake inhibitors in children with anxiety disorders.
Methods
We studied 128 children who were 6 to 17 years of age; who met the criteria for social phobia, separation anxiety disorder, or generalized anxiety disorder; and who had received psychological treatment for three weeks without improvement. The children were randomly assigned to receive fluvoxamine (at a maximum of 300 mg per day) or placebo for eight weeks and were evaluated with rating scales designed to assess the degree of anxiety and impairment.
Results
Children in the fluvoxamine group had a mean (±SD) decrease of 9.7±6.9 points in symptoms of anxiety on the Pediatric Anxiety Rating Scale (range of possible scores, 0 to 25, with higher …
Total citations
Scholar articles
JT Walkup, MJ Labellarte, MA Riddle, DS Pine… - New England Journal of Medicine, 2001
Pediatric Psychopharmacology Anxiety Study Group - N Eng J Med, 2001
JT Walkup, MJ Labellarte, MA Riddle, D Pine… - J Am Acad Child Adolesc Psychiatry, 2003
B Vitiello… - Journal of the American Academy of Child & …, 2003